Exubera: first inhaled insulin for the management of diabetes

Exubera is a dry‐powder inhaled formulation of insulin that has now gained licence approval in the UK for use in patients with both type 1 and type 2 diabetes. Here, Professor Barnett discusses the properties of this novel therapeutic option and its potential role in the current and future management of diabetes. Copyright © 2007 Wiley Interface Ltd